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We have previously reported that royal jelly (RJ) from honeybees (Apis mellifera) has weak
estrogenic activity mediated by interaction with estrogen receptors that leads to changes in gene
expression and cell proliferation. In this study, we isolated four compounds from RJ that
exhibit estrogenic activity as evaluated by a ligand-binding assay for the estrogen receptor
(ER) b. These compounds were identified as 10-hydroxy-trans-2-decenoic acid, 10-hydro-
xydecanoic acid, trans-2-decenoic acid and 24-methylenecholesterol. All these compounds
inhibited binding of 17b-estradiol to ERb, although more weakly than diethylstilbestrol or
phytoestrogens. However, these compounds had little or no effect on the binding of 17b-
estradiol to ERa. Expression assays suggested that these compounds activated ER, as evidenced
by enhanced transcription of a reporter gene containing an estrogen-responsive element.
Treatment of MCF-7 cells with these compounds enhanced their proliferation, but concomitant
treatment with tamoxifen blocked this effect. Exposure of immature rats to these compounds by
subcutaneous injection induced mild hypertrophy of the luminal epithelium of the uterus, but
was not associated with an increase in uterine weight. These findings provide evidence that
these compounds contribute to the estrogenic effect of RJ.
Keywords: Apis mellifera–2-Decenoic acid–10-Hydroxydecanoic acid–10-Hydroxy-2-decenoic
acid–24-Methylenecholesterol
Introduction
Post-menopausal women are at increased risk for many
health problems, such as hot flashes, reduced bone
density, mood swings and cardiovascular diseases (1).
The most likely cause of these problems is estrogen
deficiency. Menopausal disorders are conventionally
treated with synthetic estrogens. However, conventional
hormone replacement therapy is suspected to increase the
risk of breast cancer and to cause other undesirable side
effects, such as breast tenderness and uterine
bleeding (2,3). Because of these undesirable side effects,
many women seek more natural alternatives, such as the
so-called phytoestrogens. These alternatives include
soybean products that contain estrogen-like molecules
such as daidzein and genistein. Soybeans and soybean-
derived products have recently become common
additives in health foods and beverages. Phytoestrogens
are similar to mammalian estrogens both structurally and
functionally, and are considered to prevent menopausal
symptoms (4,5).
In addition to soybean products, royal jelly (RJ) has
become a common additive in health foods and
beverages. RJ is a viscous substance secreted by the
hypopharyngeal and mandibular glands of worker
honeybees (Apis mellifera) and is an essential food for
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properly cited.both the queen and her larvae. RJ is a mixture of many
constituents including proteins, free amino acids, lipids,
vitamins and sugars (6). 10-hydroxy-trans-2-decenoic acid
is a characteristic constituent of RJ. RJ has been reported
to exhibit physiological and pharmacological effects
in mammals, including vasodilative and hypotensive
activities, antihypercholesterolemic activity and
anti-inflammatory functions (7). In addition to these
activities, RJ has been suggested to improve menopausal
symptoms. RJ has been shown to alleviate the so-called
autonomic imbalance in menopausal women (8,9), lead-
ing to the hypothesis that RJ or its components have
effects on gene expression similar to, or mimic, the
effects of estrogen. Our previous studies in vitro and
in vivo have shown that RJ exhibits weak estrogenic
activities mediated by interaction with estrogen receptors
(ERs) that leads to changes in gene expression and
cell proliferation (10,11). A better understanding of
the components of RJ that mediate the induction of
estrogenic effects could provide the basis for the
development of new natural alternative medicines and
health food additives. In the present study, therefore,
we isolated four ERb-binding compounds from RJ




nectar and pollen from Brassicaceae Brassica campestris L.
in the Yangtze valley in the People’s Republic of
China. 17b-estradiol (E2), 17a-ethynylestradiol (17aEE2),
tamoxifen and 10-hydroxydecanoic acid (10HDA),
were purchased from Sigma (St Louis, MO, USA);
10-hydroxy-trans-2-decenoic acid (10H2DA) was obtained
from Shiono Koryo Kaisha, Ltd (Osaka, Japan); trans-
2-decenoic acid (2DEA) was from Wako Pure Chemical
Industries, Ltd (Osaka, Japan).
Ligand Binding Assay for Estrogen Receptors (ERs)
The ability of the compounds to compete with E2 for
binding to human ERa and ERb was evaluated and
compared with the activity of diethylstilbestrol using
the Ligand Screening System Estrogen Receptor




13C-NMR and H-H COSY, HSQC and
HMBC spectra were recorded with the MERCURYplus
300NB NMR instrument (Varian, Inc., Palo Alto, CA,
USA). The solvent used was deuterium methanol-d4.
Tetramethylsilane was used as an internal standard.
Isolation of Active Compounds from RJ
In this study, the following fractionations were performed
in combination with the ERb ligand-binding assay to
identify active compounds. A Quantity of 2000g of fresh
RJ with a moisture content of  67% was first extracted
with 4000ml of ethanol by stirring for 2h at room
temperature and then filtered to separate the resulting
extract into soluble and insoluble fractions. Another
4000ml of ethanol was then added to the insoluble
fraction and stirred for a further 2h at room temperature.
Insoluble precipitates were removed by filtration, and the
supernatant was combined with the soluble fraction from
the first extraction and evaporated to dryness. The
resulting material (385g) was then extracted with 2000ml
of water:chloroform (1:1). After stirring vigorously
for 10min, the mixture was separated into water and
chloroform layers. The chloroform layer was collected and
evaporated to dryness (72g) and extracted with 1000ml of
n-hexane. After stirring vigorously for 10min, the mixture
was separated into hexane-soluble and insoluble fractions
by centrifugation and each fraction was evaporated to
dryness (yield of each fraction was 5.32g and 66g,
respectively). 5.32g of the hexane-soluble fraction was
dissolved in n-hexane, applied to a column (41 300mm)
of silica gel (BW320MH; Fuji Silysia Chemical Ltd, Aichi,
Japan) and then successively eluted with 400ml of
n-hexane and 900ml of chloroform to yield 10 fractions.
The active fractions assessed by ER binding assay were
pooled, evaporated to dryness and dissolved in a small
amount of chloroform, followed by recrystalization five
times using methanol. The resulting crystal was identified
as 24-methylenecholesterol (24MET) by NMR analysis.
The solution remaining after isolation of the crystallized
material was evaporated to dryness, dissolved in chloro-
form and then applied to a column (34 240mm) of
Sephadex LH-20 (Amersham Bioscience Corp., NJ, USA).
The column was eluted with 300ml of chloroform to yield
seven fractions. The active fractions were pooled, evapo-
rated to dryness and identified as 2DEA by NMR analysis.
Five grams of the evaporated hexane-insoluble fraction
was dissolved in 40% methanol and applied to a column
(50 280mm) of ODS (Chromatorex; Fuji Silysia
Chemical Ltd). The column was eluted with 40% methanol
containing 0.1% trifluoroacetic acid to generate seven
fractions. We obtained two active fractions and identified
the active compound within these fractions as 10H2DA
and 10HDA by NMR analysis. The yields of 24MET,
2DEA, 10H2DA and 10HDA were 1.2g, 3mg, 1.65g and
0.53g, respectively.
Cell Culture and Cell Proliferation Assay
The human breast cancer cell line MCF-7 was provided
by the Cell Resource Center for Biomedical Research,
Tohoku University, Japan. Cells were maintained in
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FBS (Sigma) at 37 C in a 5% CO2 atmosphere. For
cell proliferation assays, cells were seeded in 96-well
plates at a density of 10 000 cells/100ml/well in phenol
red-free RPMI-1640 (Sigma) containing 10% charcoal
dextran-treated FBS (12). One day later, the medium was
changed and cells were incubated with 0.5nM E2 or
RJ components (commercially available 10H2DA,
10HDA and 2DEA; purified 24MET) in the presence
or absence of 1mM tamoxifen. Three to four days after
initiation of the treatment, a colorimetric proliferation
assay was performed using the MTT Cell Growth Kit as
directed by the manufacturer (Chemicon International,
Inc., Temecula, CA, USA).
Transfection and Reporter Gene Assay
MCF-7 cells were transfected with pERE-Luc
(13; provided by Dr V. C. Jordan of Northwestern
University Medical School, Chicago) and the control
plasmid pRL-TK Vector (Promega, Madison, WI, USA)
as described previously (10). Twenty-four hours after
transfection, the cells were washed and incubated in
fresh Dulbecco’s Modified Eagle Medium (Nissui
Pharmaceutical Co., Ltd, Tokyo, Japan) that contained
10% charcoal dextran-treated FBS with 0.1–10nM E2
or RJ components (commercially available 10H2DA,
10HDA and 2DEA; purified 24MET) for 24h.
A luciferase assay was performed as described previously
(10) and the luciferase activities were normalized to
control for variations in transfection efficiency using the
sea pansy-luciferase internal control and were expressed
as fold induction over the control activity. The luciferase
activities presented in this study represent the means of
the activities obtained following analyses from three
independent transfections.
Animal Protocols for In Vivo Studies
Fifteen-day-old female Sprague Dawley rats were
obtained from Japan SLC, Inc. (Hamamatsu, Japan) in
groups of  10 pups per mother. All rats were housed at
23 1 C with 55 10% humidity and fed a standard
laboratory rodent diet (CRF-1; Oriental Yeast Co.,
Ltd, Japan). Starting at post-natal day 20, the female
rats were injected subcutaneously with 2 doses of
17aEE2 (0.1 and 3mgkg
 1 day
 1) or 1gkg
 1 day
 1 RJ
or its components (commercially available 10H2DA,
10HDA and 2DEA; purified 24MET) in sesame oil
(Nacalai Tesque, Inc., Kyoto, Japan). The rats received
10mlkg
 1 body weight of the control or test solutions
once a day for three days. The injections were
administered between 10 and 11A.M. each day.
Controls received 10mlkg
 1 of sesame oil once a day
for three days. Twenty-seven hours after the last injection
on post-natal day 23, the rats were sacrificed and each
uterus was rapidly excised by severing just above the
vagina, and leaving the ovaries attached. After weighing,
the uterus was rapidly fixed in Bouin’s solution for
histological analysis. All animal studies were conducted
in accordance with the internationally accepted principles
for laboratory animal use and care (14).
Histology
Uteri from rats in each dose group were fixed in Bouin’s
solution for 24h, dehydrated and embedded in paraffin.
Serial 8mm cross sections were made through the uterine
horns, and stained with hematoxylin and eosin.
The height of the epithelial cells lining the lumen along
the uterus was measured in tissue sections from the mid-
region of each uterine horn as described previously (15)
with slight modification. In brief, the epithelial cell
heights in the rats shown in Table 1 were measured in
five different areas from five sections at intervals
of  160mm from rats shown in Table 1 using a light
microscope (Zeiss Axiovert S100TV).
Data Analysis
Dunnett’s test was performed to assess the significance of
differences between control and test groups.
Table 1. Effects of RJ and its components on uterine wet weight
Group and dose N Body weight (g) Uterus (mg) Uterus/body weight
Mean SD Mean SD
Control 17 48.3 4.3 26.6 4.6 0.56
17aEE2 (0.1mgkg
 1) 12 47.9 6.7 41.0** 13.5 0.87
17aEE2 (3mgkg
 1) 5 47.1 3.5 115** 11.5 2.5
RJ (1gkg
 1) 12 49.1 5.5 26.9 3.6 0.55
10H2DA (1gkg
 1) 8 42.9* 7.5 25.9 9.8 0.59
10HDA (1gkg
 1) 11 45.8 5.8 25.2 3.3 0.55
2DEA (1gkg
 1) 8 45.9 6.9 22.9 3.9 0.51
24MET (1gkg
 1) 8 47.5 6.2 25.9 2.9 0.55
Note: Asterisks indicate values that are significantly different (*P50.05; **P50.01) from vehicle control values.
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Identification of Estrogenic Compounds from RJ
We have previously reported that RJ exhibits estrogenic
activities that are mediated by interaction with ERs,
leading to changes in gene expressions and cell prolifera-
tion (10,11). In this study, we aimed to identify the
constituents in RJ responsible for the estrogenic effects
using an ERb ligand-binding assay. We attempted to
purify the active constituents in RJ following solvent
extraction and distribution, column chromatography and
recrystalization. We used NMR analysis to identify four
compounds from RJ with affinity for ERb: 10H2DA,
10HDA, 2DEA and 24MET. The spectra of the purified
10H2DA, 10HDA and 2DEA were consistent with those
observed following analysis of the comparable commer-
cially available reagents. The spectrum observed follow-
ing analysis of the purified 24MET was consistent with
that previously reported (16). The structures of the four
compounds are shown in Fig. 1. We next evaluated the
affinities of 10H2DA, 10HDA, 2DEA or 24MET for
ERs by comparing the abilities of these compounds,
relative to that of diethylstilbestrol, to compete with E2
for binding to the ERa and ERb. 10H2DA, 10HDA,
2DEA or 24MET inhibited the binding of E2 to the ERb
in a concentration-dependent manner, but these com-
pounds had little or no effect upon the ability of E2 to
bind to ERa (Fig. 2). The IC50 of 10H2DA, 10HDA,
2DEA and 24MET that inhibited binding of E2 to ERb
were estimated to be 90, 140, 17 and 6.0mM, respectively.
The IC50 of diethylstilbestrol to inhibit binding to ERb
under the corresponding conditions was 21nM. The
affinities of RJ components for the ERb were  2–4
orders of magnitude lower than that of diethylstilbestrol.
Enhanced Transcription of a Reporter Gene and
Cell Proliferation by RJ Components
We next examined the effects of 10H2DA, 10HDA,
2DEA and 24MET on the activation of ER(s) using a
reporter gene assay. We evaluated the ability of these
compounds to stimulate transcription following transient
transfection of MCF-7 cells with a reporter plasmid
(pERE-Luc) (13) expressing the luciferase gene under the
transcriptional control of the Xenopus vitellogenin A2
estrogen response element (ERE). Exposure of trans-
fected cells to various concentrations of the RJ com-
pounds led to increased levels of luciferase activity in a
dose-dependent manner (Fig. 3). These results suggest
that these compounds activate ER(s) resulting in
enhanced transcription from pERE-Luc via the ERE.
The effects of the RJ components on proliferation of
MCF-7 cells were determined using a methylthiazolyldi-
phenyl-tetrazolium bromide (MTT) assay. The addition
of each compound increased the rate of proliferation of
MCF-7 cells at concentrations of 0.01–0.1mM, although
Figure 1. Chemical structures of (A) 10-hydroxy-trans-2-decenoic
acid (B) 10-hydroxydecanoic acid (C) trans-2-decenoic acid and
(D) 24-methylenecholesterol.
Figure 2. Binding affinities of RJ-derived estrogenic compounds for
ERs. The ability of 10H2DA (open triangle), 10HDA (closed circle),
2DEA (closed triangle) and 24MET (open circle) to inhibit E2 binding
to ERa and ERb were evaluated and compared with that of
diethylstilbestrol (open square) as described in ‘Methods’. The mean
from two experiments is shown.
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E2 (Fig. 4A). Stimulation of cell proliferation mediated
by these compounds was blocked by 1mM tamoxifen, an
estrogen antagonist that also inhibited stimulation of
growth by E2, but which had no effect on proliferation
when administered alone (Fig. 4B). These results indicate
that the estrogenic action of 10H2DA, 10HDA, 2DEA or
24MET on MCF-7 cell proliferation is mediated by
signaling through the estrogen receptor.
Mild Hypertrophy of the Uterine Luminal Epithelium
Induced by RJ or its Components
The uterotrophic response in immature rodents and adult
ovariectomized rats can be used as a measure of estrogen-
like activity of compounds in vivo (17). In the rat, the
concentration of E2 is consistently low throughout
prepubertal development, but starts to increase after
post-natal day 28 with a large increase one day before the
first ovulation (18). However, exposure of rats to
estrogens during the prepubertal period can induce a
uterotrophic response that is characterized by a reversible
modification of the morphology and physiology of the
uterus. We evaluated the effects on the uterus following
exposure of 20-day old female rats to RJ, the estrogenic
compounds we purified from RJ (10H2DA, 10HDA,
2DEA or 24MET), and 17aEE2, by subcutaneous
injection for 3 days. All treatments were well-tolerated
by the rats. We observed no evidence of overt toxicity or
clinical signs of toxicity. Premature vaginal opening was
not detected in any of the rats. 17aEE2 led to a
significant (P50.01) increase in uterine wet weight at
doses of 0.1 and 3mgkg
 1day
 1, producing an increase in
wet uterine weight of over 1.5-fold compared with
vehicle-treated controls (Table 1). No significant changes
in wet uterine weight were observed in rats exposed to RJ
or its components (Table 1).
Histological effects of these agents on immature uterine
epithelial cell height are shown in Fig. 5, and are
quantified in Fig. 6. 17aEE2 at a dose of 3mgkg
 1
day
 1 induced marked hypertrophy of the luminal
epithelium, whereas only a mild increase in luminal
height was observed in uteri treated with 17aEE2 at
0.1mgkg
 1day
 1 (Fig. 5). Although an increase in uterine
weight in response to exposure to RJ or its components
was not detected, they did induce mild but statistically
significant hypertrophy of the luminal epithelium com-
pared with the vehicle-treated controls (Figs 5 and 6).
Altogether, the effects of exposure to 17aEE2 at
0.1mgkg
 1day
 1, or RJ or its components, on hyper-
trophy of the luminal epithelium were indistinguishable
from each other at the histological level.
Discussion
We have previously shown that RJ has estrogenic
activities and suggested it contains estrogenic components
(10,11). In the current study, we isolated four compounds
from RJ (10H2DA, 10HDA, 2DEA and 24MET) that
exhibit ERb-binding activity. We used several assays to
Figure 3. Reporter gene expression assays using MCF-7 cells transfected transiently with pERE-Luc. The transfected cells were incubated with
10H2DA, 10HDA, 2DES or 24MET for 24h and luciferase activities were measured. Data are expressed as fold induction over the negative control,
and are plotted as the mean and SD of three experiments. An asterisk (
**) indicates values that are significantly different (P50.01) from control
values.
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ERE-based reporter gene expression assays suggested
that these compounds activated ERs, leading to tran-
scriptional activation via an ERE (Fig. 3). We further
observed that these compounds stimulated the prolifera-
tion of MCF-7 cells, which have been shown to respond
to estrogens (Fig. 4). Concomitant treatment with
tamoxifen blocked this effect. Thus, all in vitro data
indicate that 10H2DA, 10HDA, 2DEA and 24MET elicit
the full sequence of estrogenic action.
RJ comprises 60–70% water, 12–15% proteins, 10–12%
carbohydrates, 3–7% lipids (including sterols and fatty
acids) and traces of mineral salts and vitamins (19).
24MET constitutes 49–58% of RJ sterols (20). 10H2DA
and 10HDA are characteristic fatty acids of RJ,
together representing 60–80% of the organic acid content
of RJ, whereas 2DEA is present at a much lower
level (21). 10H2DA has been reported to have anti-
bacterial (22), antitumor (23) and insulin-like (24)
activities. 10H2DA and 10HDA have also been shown
to promote collagen production by skin fibroblasts (25).
However, little information is available concerning the
pharmacological effects of either 24MET or 2DEA.
To our knowledge, this is the first report demonstrating
the estrogenic effects of 24MET, 2DEA, 10H2DA or
10HDA, although these compounds are not as potent as
steroid estrogens.
10H2DA, 10HDA, 2DEA and 24MET have rather
weak binding affinities for ERb compared with
diethylstilbestrol (10
 2–10
 4-fold) (Fig. 2), circulating E2
(10
 3–10
 5-fold), genistein (10
 3–10
 4-fold) or daidzein
(10
 1–10
 3-fold) (26). However, the concentrations of
these compounds in RJ are much greater than those of
the endogenous steroid estrogens found under physiolo-
gical conditions. The high concentrations of these
compounds in RJ could, partly at least, account for the
pharmacological effects attributed to RJ, including
improvement of menopausal symptoms (8,9), bone
formation (27) and prevention of osteoporosis (28),
although further analysis is necessary.
The weight increase induced in the immature uterus of
the rat by exposure to ethynylestradiol is characteristic of
Figure 4. Effects of RJ-derived compounds on the proliferation of MCF-7 cells. (A) MCF-7 cells were incubated with 0.001–0.1mM 10H2DA,
10HDA, 2DEA or 24MET for three days, and then subjected to the MTT assays. As a positive control, cells were treated with 0.5nM E2. Asterisks
indicate values that are significantly different (
*P50.05;
**P50.01) from untreated control values. (B) MCF-7 cells were incubated with 0.5nM E2,
0.1mM 10H2DA, 0.01mM 10HDA, 0.1mM 2DEA or 0.01mM 24MET with/without 1mM tamoxifen for three days prior to the MTT assay.
Asterisks indicate values that are significantly different (
*P50.05;
**P50.01) from untreated control (without tamoxifen) values. Results shown in
(A) and (B) represent the mean and SD from six experiments.
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The uterine wet weight increase induced by 17aEE2
results from hypertrophy and hyperplasia, as well as
accumulation of fluid in the lumen (15). Although we did
not detect an increase in the uterine wet weight in
response to exposure of the immature rat uterus to
10H2DA, 10HDA, 2DEA or 24MET, we did observe
mild hypertrophy of the luminal epithelium (Figs 5 and 6;
Table 1). These observations may be explained by
differences in the pattern of expression of ER subtypes
in rat tissues. ERa rather than ERb is predomi-
nantly expressed in the uterus (29). Our data shows
that 10H2DA, 10HDA, 2DEA and 24MET bind
preferentially to ERb rather than ERa (Fig. 2), which
may explain why we only observe a slight increase in
epithelial cell height, and no increase in uterus weight, in
response to treatment of immature rats with these
compounds.
Earlier studies have shown that unsaturated fatty
acids, but not saturated fatty acids, modulate estrogen
and/or ER(s) by alterations in estradiol binding to
receptors (30), and/or by cleaving native ER(s) (31).
Linoleic acid, an unsaturated fatty acid, was isolated
from chaste-tree berries as an estrogenic compound
utilizing ERb binding as a monitor (32). Thus, unsatu-
rated fatty acids have been shown to modulate and/or
induce some estrogenic effects via interaction with
estrogen and/or ERs. Other studies suggest that non-
esterified fatty acids may influence cell growth and
proliferation by modifying membrane fluidity (33). Our
data indicate that 10H2DA, 10HDA, 2DEA and 24MET
interact with ER, activate ERs resulting in enhanced
transcription of reporter gene via the ERE and enhance
MCF-7 cell proliferation. 10H2DA, 10HDA and 2DEA
are similar in their molecular structure, although 10HDA
is saturated whereas 10H2DA and 2DEA are both
unsaturated fatty acids. The results suggest that saturated
fatty acids can also exhibit estrogenic activity.
In summary, we isolated and identified four compounds
associated with the estrogenic effects of RJ. Further
understanding of these compounds should provide a
scientific basis for the development of better therapeutic
applications of dietary supplement for the improvement
of quality of life in menopausal women.
Figure 5. Uterotrophic response in immature rats injected with vehicle control (A), 0.1mgkg
 1 17aEE2 (B), 3mgkg
 1 17aEE2 (C), RJ (D),
10H2DA (E), 10HDA (F), 2DEA (G) or 24MET (H). Tissue sections from the mid-region of each uterine horn are shown. Bar: 20mm.
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Figure 6. Luminal epithelial cell height of the uterus from immature rats
injected with vehicle control (A), 0.1mgkg
 1 17aEE2 (B), 3mgkg
 1
17aEE2 (C), RJ (D), 10H2DA (E), 10HDA (F), 2DEA (G) or
24MET (H). Tissue sections from the mid-region of each uterine horn
were evaluated for epithelial cell height of the epithelial lining of the
lumen along the uterus. The epithelial cell height was measured in five
different areas comprising five sections at approximately 160mm
intervals from the rats shown in Table 1. Data are expressed as the
mean and SD. Asterisks indicate values that are significantly different
(
*P50.05;
**P50.01) from control values.
302 Estrogenic compounds from royal jelly